Accretion Pharmaceuticals Ltd. · NSE:ACCPL
Accretion Pharmaceuticals — Investor Presentation (May 2026)
38 slides from Accretion Pharmaceuticals's investor presentation, May 15, 2026
Slide 1: Cover letter to National Stock Exchange of India
Date: 15th May, 2026 To, Corporate Relations Department National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Company Code: ACCPL Dear Sir/ Madam, Subject: Investors/ Analysts Presentation for the year ended on 31st March, 2026 Purs
Slide 2: Investor Presentation May 2026
Pharmaceuticals Limited Investor Presentation May 2026
Slide 3: Disclaimer
Disclaimer This presentation contains “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Accretion Pharmaceuticals Limited (APL) and its group companies’ future business developments and
Slide 4: Table of Content
Table of Content Company Overview Business Overview Industry Overview Financial Highlights Way Ahead
Slide 5: Company Overview
Company Overview
Slide 6: Accretion at a glance
Accretion at a glance Leading manufacturer of high-quality Experienced Management Team Modern manufacturing facility Certifications pharmaceutical formulations and Headquartered in Ahmedabad, WHO- cGMP, GLP, Cambodia GMP, Significant experience in contract development manufacturing Gujarat Rwa
Slide 7: Vision & Mission
Vision & Mission Mission Our mission is to deliver state-of-the-art pharmaceutical manufacturing solutions that exceed client expectations. We are committed to combating diseases and advancing global health through innovative, high-quality medicines offered at competitive prices, striving towards a
Slide 8: Journey So Far
Journey So Far Listed on the National Stock Exchange (NSE) SME Platform in mid- May 2025 2023 Received cGMP (Current Good Manufacturing Practices) approval from regulatory authorities of Malawi & Nigeria for its Obtained ISO Certification 9001:2015, ISO Certification 14001:2015 and manufacturi
Slide 9: Experienced Management Team
Experienced Management Team Mr. Vivek Ashok Kumar Patel Mr. Harshad Nanubhai Rathod Mr. Hardik Mukundbhai Prajapati Mr. Mayur Popatlal Sojitra Ms. Roshani Shah Promoter and Managing Promoter, Executive Promoter and Executive Promoter and Executive Company Secretary & Director Director & CFO Director
Slide 10: Key Strengths
Key Strengths Visionary Leadership Over decade of experience in this business supported by team of professionals having knowledge of our Strong Relationships various business functions Long-standing relationships with clients and suppliers fostering loyalty and industry reputation Collects fee
Slide 11: Business Overview
Business Overview
Slide 12: Our Comprehensive Therapeutic Offerings
Our Comprehensive Therapeutic Offerings Key Key Product by Dosage Therapeutic Therapeutic Dosage Forms Forms Segment Segments Anti Malarial Tablets Antifungal & Anti Bacterial Anti Inflammatory Antihistamine Capsules Antiallergics Antibiotic Oral Liquids Antitussives Anticold
Slide 13: Dosage Forms - Tablets
Dosage Forms - Tablets Antibiotic Revenue Contribution (Rs. In Crore) 28.8 Antibacterial 20.2 Antifungal 12.2 13.4 10.0 Anti- Inflammatory Antihistamine FY22 FY23 FY24 FY25 FY26 Antiallergics Capacity and Capacity Utilization (In Crore) Antitussives Utilized Anticold Capacity, 65.72 Antiulcer and An
Slide 14: Dosage Forms - Capsules
Dosage Forms - Capsules Revenue Contribution (Rs. In Crore) Antibacterial 16.9 9.0 4.8 5.4 3.9 Antifungal FY22 FY23 FY24 FY25 FY26 Anti- Inflammatory Capacity and Capacity Utilization (In Crore) Utilized Capacity, 22.34 Antiulcer and Antacid 49.65% Cardiac and Anti-Hypertensive Utilizations Installe
Slide 15: Dosage Forms – Oral Liquids
Dosage Forms – Oral Liquids Antibiotic Revenue Contribution (Rs. In Crore) Antibacterial 20.9 11.5 Antifungal 8.5 10.0 6.3 Antihistamine FY22 FY23 FY24 FY25 FY26 Antiallergics Antitussives Capacity and Capacity Utilization (In Crore) Anticold Utilized Capacity, 1.49 Antiulcer and Antacid 68.40% Vita
Slide 16: Dosage Forms – External Preparations
Dosage Forms – External Preparations Revenue Contribution (Rs. In Crore) Antibiotic 16.3 9.9 Antibacterial 2.9 3.8 1.9 FY22 FY23 FY24 FY25 FY26 Antifungal Capacity and Capacity Utilization (In Crore) Anti-Inflammatory Utilized Capacity, 0.57 Antipruritic 63.10% Utilizations Antiulcer Installed Capac
Slide 17: Dosage Forms – Oral Powders
Dosage Forms – Oral Powders Revenue Contribution (Rs. In Crore) Antibiotic 6.8 6.8 Antibacterial 0.9 1.0 Antifungal 0.2 FY22 FY23 FY24 FY25 FY26 Antihistamine Capacity and Capacity Utilization(In Crores) Antiallergics Utilized Capacity, 7.06 Antitussives 45.91% Anticold Utilizations Installed Antiul
Slide 18: With state of art manufacturing facility
…With state of art manufacturing facility Manufacturing facility Granulation Liquid Filling & Sealing Micro lab QC lab QC lab HPLC Tableting Machine Plant Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat External Dosage Tablet Capsules Oral Liquid Oral Pow
Slide 19: Creating Strong Global Presence since 2012
…Creating Strong Global Presence since 2012 International Direct network across 30 countries Africa, Southeast Asia, and Latin America Countries exported through Merchant Exporters include Congo, Libya, Angola, Botswana, Venezuela and Cambodia More than 70 merchant exporters Domestic Domes
Slide 20: Our Certification
Our Certification Accreti@n Pharmaceuticals Limited ay ‘Registration 19
Slide 21: Reward & Recognition
7 Accretion’ Reward & Recognition Accretne Glam India Event
Slide 22: Industry Overview
Industry Overview
Slide 23: India: Pharmacy of the World
India : Pharmacy of the World Indian Pharmaceutical Industry Exports ($ billion) Global Pharmaceutical Market (Us $ Billion) The Indian Pharma industry is the world’s 3rd largest by 30.4 3148.31 27.9 volume and 14th by value 24.6 25.4 22.4 1661.26 1763.90 FY 2024-25 turnover: Rs. 2,26,000 Cr, growth
Slide 24: CDMO Industry Overview
CDMO Industry Overview Global CDMO Industry Indian CDMO Industry Role & Importance of CDMOs • End-to-end services from drug development to commercial production, helping India’s CDMO sector is set to double from USD 22.5 Billion to USD pharma firms cut costs, scale faster, and access advanced techno
Slide 25: Financial Overview
mlalelarere| Overview
Slide 26: Management Comment
Management Comment “We are pleased to report a strong financial and operational performance for FY26, marked by robust revenue growth and continued expansion across key business areas. During the year, the Company achieved a total income of ₹89.63 crore, reflecting a growth of 56.21% YoY, while Prof
Slide 27: CSR Update
CSR Update Contributed ₹ 12,11,111 to the Lilavati Foundation towards the construction of its new building in Ahmedabad This contribution reflects the Company’s commitment to supporting social infrastructure and community development initiatives, while reinforcing its focus on creating a positiv
Slide 28: Responsible Manufacturing. Sustainable Future
Responsible Manufacturing. Sustainable Future Solar Power Utilization In-house rooftop solar installation reduces grid dependence and lowers operational carbon footprint Energy-Efficient Machinery Modern manufacturing equipment designed for optimised energy consumption and improved operational effic
Slide 29: Half Yearly Financial Highlights
Half Yearly Financial Highlights Particulars (Rs. in Crore) H2 FY26 H2 FY25 YoY% H1 FY26 Total Income from Operations 45.89 38.81 18.24% 43.74 Raw Materials 33.00 27.93 32.15 Employee Cost 2.43 2.13 2.06 Revenue in H2 FY26 stood at Rs. 45.89 Other Expenses 2.58 1.21 2.45 crore, up 18.24% YoY, driven
Slide 30: Financial Highlights - Annually
Financial Highlights - Annually Revenue (Rs. Cr) EBITDA* (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 16 22.3% 25% 12 11.8% 14% 89.6 20.7% 15.0 11.5% 14 10 10.8% 12% 16.7% 20% 12 8 9.7 10% 57.4 10 11.9 15% 8% 8 6 6.8 6% 33.7 6 7.4% 6.8% 7.5 10% 29.4 4 4% 22.3 4 3.9 5% 2 0.4% 0.4% 2% 2 0.1 1.6 2.0
Slide 31: Annual Financial Highlights
Annual Financial Highlights Particulars (Rs. in Crore) FY26 FY25 FY24 FY23 FY22 Total Income from Operations 89.63 57.38 33.67 29.38 22.29 Raw Materials 65.15 39.91 21.61 23.35 17.56 Employee Cost 4.49 3.67 2.62 2.47 1.96 Other Expenses 5.04 1.91 1.95 1.57 1.13 Total Expenditure 74.68 45.50 26.18 27
Slide 32: Balance Sheet Highlights
Balance Sheet Highlights Rs. Crore Rs. Crore Liabilities FY26 FY25 FY24 FY23 FY22 Assets FY26 FY25 FY24 FY23 FY22 Shareholder’s Funds 54.71 15.29 5.35 3.84 3.08 Non-current assets 16.06 6.33 5.46 6.05 5.86 Share capital 11.12 8.17 4.00 3.84 3.08 Property,Plant & 13.21 6.09 5.27 6.01 5.84 Equipment R
Slide 33: Key Ratios
Key Ratios RoE(%) RoA(%) 72.5% 17.0% 14.3% 12.6% 44.4% 17.7% 2.6% 2.7% 0.5% 0.5% FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 RoCE(%) Total Debt to Equity Ratio (X) 36.5% 38.1% 2.5 2.5 2.2 20.8% 10.5% 0.9 9.8% 0.2 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 RoE = Net Profit/Total Equity |
Slide 34: Working Capital Analysis (Days)
Working Capital Analysis (Days) Inventory Receivables 91 156 74 72 131 66 62 112 116 96 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Payables Net Working Capital 183 157 147 145 128 116 73 79 48 23 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 33 33
Slide 35: Way Ahead
Way Ahead
Slide 36: Way Forward
Way Forward Geographical Diversification Strengthening presence across Asia and Africa by moving from merchant exports to direct market engagement 01. Driving growth through expanded product registrations and local distributors to deliver high-quality pharmaceuticals sustainably New Product Deve
Slide 37: ESG Highlights
ESG Highlights Embedding sustainability, people and responsible governance into our operating model Environmental Responsibility Social Commitment Towards a Low-Carbon Future ■ Focus on reducing environmental impact ■ Building a skilled and growth-oriented ■ Energy-efficient manufacturing infrastruc
Slide 38: Thank You
Thank You Company : Investor Relations Advisors : Accretion Pharmaceuticals Limited. Adfactors PR Pvt. Ltd. CS Roshni Shah Mr. Rupesh Rege / Mr. Chaitanya Satwe/ Ms. Mousami Chavan compliance@accretionpharma.com rupesh.rege@adfactorspr.com chaitanya.satwe@adfactorspr.com mousami.chavan@adfactors.pr.
Accretion Pharmaceuticals — Investor Presentation (May 2026) on 6ix